Severe Aplastic Anemia
Information
- Disease name
- Severe Aplastic Anemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03192397 | Active, not recruiting | Phase 1/Phase 2 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | August 9, 2017 | May 21, 2027 |
| NCT02845596 | Active, not recruiting | N/A | Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia | August 2016 | April 2024 |
| NCT01966367 | Active, not recruiting | Phase 1/Phase 2 | CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation | March 2013 | February 2030 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT03825744 | Active, not recruiting | Phase 3 | Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | March 5, 2019 | December 2024 |
| NCT01193283 | Completed | Phase 1/Phase 2 | Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia | August 2010 | September 2014 |
| NCT00001964 | Completed | Phase 2 | Combination Therapy of Severe Aplastic Anemia | March 17, 2000 | May 12, 2015 |
| NCT00004143 | Completed | Phase 2 | Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes | September 1999 | June 2009 |
| NCT00061360 | Completed | Phase 2 | Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia | June 26, 2003 | September 8, 2015 |
| NCT00516152 | Completed | Phase 2 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | November 2002 | November 2007 |
| NCT01187017 | Completed | Phase 1/Phase 2 | A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia | August 2010 | July 2012 |
| NCT01364363 | Completed | N/A | Unrelated Donor Stem Cell Transplantation | March 2005 | July 2015 |
| NCT01586455 | Completed | Phase 1 | Human Placental-Derived Stem Cell Transplantation | April 2013 | September 2022 |
| NCT01703169 | Completed | Phase 2 | Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia | November 2012 | June 2016 |
| NCT01768845 | Completed | N/A | Unrelated Umbilical Cord Blood (UBC)Transplantation | February 3, 2009 | April 6, 2021 |
| NCT01917708 | Completed | Phase 1 | Bone Marrow Transplant With Abatacept for Non-Malignant Diseases | January 2014 | September 19, 2019 |
| NCT02065154 | Completed | Phase 2 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | August 27, 2013 | April 2022 |
| NCT02099747 | Completed | Phase 3 | hATG+CsA vs hATG+CsA+Eltrombopag for SAA | July 2015 | December 2020 |
| NCT02224872 | Completed | Phase 2 | Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia | August 2014 | December 2021 |
| NCT02745717 | Completed | Phase 4 | The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia | January 2016 | December 2021 |
| NCT02833805 | Completed | Phase 2 | NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia | September 2016 | July 2021 |
| NCT02918292 | Completed | Phase 2 | Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) | July 3, 2017 | August 17, 2021 |
| NCT02998645 | Completed | Phase 2 | Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia | May 11, 2017 | May 30, 2022 |
| NCT03557099 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient | June 20, 2018 | July 23, 2020 |
| NCT04436367 | Completed | Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy | June 15, 2020 | March 15, 2022 | |
| NCT04436380 | Completed | Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy | June 15, 2020 | March 15, 2023 | |
| NCT05049668 | Enrolling by invitation | RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial | October 2021 | December 2034 | |
| NCT05419843 | Not yet recruiting | Phase 2 | Up-front Matched Unrelated Donor Transplantation in Pediatric Patients With Idiopathic Aplastic Anemia | June 2022 | June 2027 |
| NCT06279494 | Not yet recruiting | Phase 1/Phase 2 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | March 2024 | March 2025 |
| NCT06039436 | Recruiting | Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT | October 2023 | May 31, 2025 | |
| NCT06069180 | Recruiting | Phase 4 | The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA | November 15, 2023 | December 31, 2025 |
| NCT02979873 | Recruiting | Phase 2 | Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy | December 19, 2016 | August 31, 2024 |
| NCT06254560 | Recruiting | Phase 2 | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | February 23, 2023 | December 30, 2027 |
| NCT03173937 | Recruiting | Phase 1/Phase 2 | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome | June 13, 2017 | March 1, 2028 |
| NCT05975996 | Recruiting | Phase 2 | Cyclophosphamide Added to Standard Immunosuppressive Therapy With Eltrombopag as Front-line Therapy in Patients With Severe Aplastic Anemia | July 10, 2023 | June 30, 2027 |
| NCT05998408 | Recruiting | Phase 1/Phase 2 | JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure | February 20, 2024 | June 3, 2032 |
| NCT02828592 | Recruiting | Phase 2 | Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia | September 9, 2016 | August 31, 2026 |
| NCT04304820 | Recruiting | Phase 2 | Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) | May 7, 2020 | May 31, 2028 |
| NCT04356469 | Recruiting | Phase 2 | TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children | July 22, 2020 | June 30, 2025 |
| NCT06378060 | Recruiting | Phase 2 | Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia | March 1, 2024 | April 1, 2027 |
| NCT06412497 | Recruiting | Phase 2 | MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. | June 5, 2024 | May 1, 2036 |
| NCT05012111 | Recruiting | Natural History of Acquired and Inherited Bone Marrow Failure Syndromes | October 25, 2021 | February 4, 2041 | |
| NCT01351545 | Recruiting | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | October 2011 | October 2041 | |
| NCT05236764 | Recruiting | N/A | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion | December 6, 2023 | August 1, 2030 |
| NCT01623167 | Recruiting | Phase 1/Phase 2 | Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia | July 2, 2012 | January 30, 2029 |
| NCT05433922 | Recruiting | N/A | Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly | June 1, 2022 | December 31, 2024 |
| NCT05531279 | Recruiting | N/A | A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency | June 5, 2022 | January 5, 2026 |
| NCT01174108 | Recruiting | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells | December 10, 2010 | June 30, 2028 |
| NCT05600426 | Recruiting | Phase 3 | A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | January 25, 2023 | December 2029 |
| NCT05720234 | Recruiting | Phase 2 | Avatrombopag Combined With IST as First-line Treatment for SAA | November 10, 2022 | November 30, 2024 |
| NCT03579875 | Recruiting | Phase 2 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | November 13, 2018 | January 5, 2029 |
| NCT04099966 | Recruiting | Phase 2 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | April 1, 2021 | December 31, 2026 |
| NCT00212407 | Terminated | Early Phase 1 | New York Blood Center National Cord Blood Program | February 1993 | November 10, 2011 |
| NCT00358657 | Terminated | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders | May 24, 2006 | May 25, 2019 |
| NCT00590460 | Terminated | Phase 1/Phase 2 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | July 2001 | September 2009 |
| NCT01383434 | Terminated | Phase 2 | Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia | June 2011 | August 2014 |
| NCT01319851 | Terminated | N/A | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation | September 2010 | September 2013 |
| NCT01997372 | Unknown status | Phase 4 | Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia | December 2010 | November 2015 |
| NCT03295058 | Unknown status | Phase 2/Phase 3 | Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients | January 1, 2019 | June 2020 |
| NCT03836690 | Unknown status | Phase 1 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation | October 21, 2019 | April 1, 2023 |
| NCT02407470 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia | January 2015 | July 2017 |
| NCT03246178 | Unknown status | N/A | Haploidentical Transplantation in Severe Aplastic Anemia | July 10, 2017 | December 1, 2020 |
| NCT01472055 | Unknown status | Phase 2 | Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation | October 2011 | September 2014 |
| NCT02247973 | Unknown status | Phase 2 | Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. | February 2013 | February 2018 |
| NCT01129323 | Withdrawn | N/A | Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | November 2009 |